Panacea Biotec Ltd's Q4FY25 Quarter Results
- 31 May 2025
Result Summary
- Panacea Biotec Ltd reported a 11.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 2.3%.
- Its expenses for the quarter were down by 8.1% QoQ and up 4.8% YoY.
- The net profit decreased 144.8% QoQ and decreased 84.3% YoY.
- The earnings per share (EPS) of Panacea Biotec Ltd declined at 0.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 147.27 | 167.11 | 143.99 | -11.9% | 2.3% |
Total Expenses | 152.13 | 165.50 | 145.16 | -8.1% | 4.8% |
Profit Before Tax | -2.12 | 4.38 | 18.21 | -148.4% | -111.6% |
Tax | -0.13 | -0.06 | 30.89 | 116.7% | -100.4% |
Profit After Tax | -1.99 | 4.44 | -12.68 | -144.8% | -84.3% |
Earnings Per Share | -0.20 | 0.70 | -2.10 | -128.6% | -90.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Panacea Biotec Ltd is a pharmaceutical and biotechnology company known for its development and manufacturing of vaccines and pharmaceutical formulations. The company operates primarily in the healthcare and life sciences industry, focusing on the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. As of the last known data up to October 2023, Panacea Biotec has been involved in various healthcare initiatives and partnerships to enhance its product offerings. However, specific recent major developments beyond this timeframe are not available.
Revenue
For the fourth quarter of the fiscal year 2025 (Q4FY25), Panacea Biotec Ltd reported a total income of ₹147.27 crores. This represents a year-over-year increase of 2.3% compared to the same quarter in the previous year (Q4FY24), where the total income was ₹143.99 crores. However, when compared to the preceding quarter (Q3FY25), there was a quarter-over-quarter decline of 11.9% from ₹167.11 crores. This fluctuation in revenue between quarters may reflect various operational and market dynamics that are not detailed in the provided data.
Profitability
In the profitability segment, Panacea Biotec Ltd experienced a challenging quarter in Q4FY25, recording a loss before tax of ₹2.12 crores. This was a significant decline compared to both the previous quarter (Q3FY25), where the company reported a profit before tax of ₹4.38 crores, and the year-ago quarter (Q4FY24), which saw a profit before tax of ₹18.21 crores. The percentage change in profit before tax was -148.4% QoQ and -111.6% YoY. The tax expense for Q4FY25 was a negative ₹0.13 crores, compared to a negative tax of ₹0.06 crores in Q3FY25 and a positive tax of ₹30.89 crores in Q4FY24. The resulting profit after tax for Q4FY25 was a loss of ₹1.99 crores, contrasting sharply with a profit of ₹4.44 crores in the previous quarter and a wider loss of ₹12.68 crores in the same quarter last year.
Operating Metrics
The earnings per share (EPS) for Panacea Biotec Ltd in Q4FY25 was reported at -₹0.20. This reflects a decrease when compared to Q3FY25, where the EPS was ₹0.70, indicating a quarter-over-quarter percentage change of -128.6%. However, there was an improvement from the year-ago quarter (Q4FY24), where the EPS was -₹2.10, showing a year-over-year percentage change of -90.5%. Total expenses for Q4FY25 amounted to ₹152.13 crores, which is a decrease of 8.1% from the previous quarter's expenses of ₹165.50 crores, but an increase of 4.8% compared to the expenses of ₹145.16 crores in the fourth quarter of the previous year. These metrics highlight the financial dynamics of the company's operations over the reported periods.